-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Update in Hemophilia

Program: Education Program
Hematology Disease Topics & Pathways:
Biological therapies, Clinical Practice (Health Services and Quality), Gene Therapy, Therapies
Saturday, December 10, 2022: 4:00 PM-5:15 PM
291-292 (Ernest N. Morial Convention Center)
Chair:
Rebecca Kruse-Jarres, MD, University of Washington School of Medicine
Disclosures:
Kruse-Jarres: Pfizer: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Speakers Bureau; Takeda: Speakers Bureau; Genentech: Research Funding.
Long-Term Prophylaxis - What Are Our Options and How to Define Success?

Marilyn J Manco-Johnson, MD

Hemophilia &Thrombosis Center, Department of Pediatrics, University of Colorado, Aurora, CO; Hemophilia & Thrombosis Center, Department of Pediatrics, Mountain State Regional Hemophilia %26 Thrombosis Ctr., Aurora, CO
Peri-Operative Hemostasis

Rebecca Kruse-Jarres, MD

WACBD, Seattle, WA
Gene Therapy

Amit C. Nathwani, MD, PhD

Department of Haematology, Cancer Institute, University College London, London, ENG, United Kingdom
See more of: Education Program
<< Previous Session | Next Session >>